NEW HAVEN, Conn., March 14, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company's programs in HIV, HCV and serious bacterial infections at the 28th Annual Cowen & Company Healthcare Conference on Monday, March 17, 2008 at 3:15 p.m. at The Boston Marriott Copley Place.
The live audio broadcasts and the subsequent archived webcasts of the Company presentations will be available on the Company's website, www.achillion.com, under the "News Center" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease - HIV, hepatitis and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000.
CONTACT: Achillion Pharmaceuticals, Inc. Investors: Mary Kay Fenton (203) 624-7000 firstname.lastname@example.org MacDougall Biomedical Communications Media: Kari Watson (781) 235-3060 email@example.com